Glycated Hemoglobin Measurement and Prediction of Cardiovascular Disease

Abstract

To help achieve reductions in diabetes-specific microvascular complications, guidelines recommend screening people for diabetes mellitus by assessing glycemia measures, such as fasting blood glucose levels and levels of glycated hemoglobin (HbA_1c), a measure of glucose exposure over the previous 2 to 3 months.^1,2 Furthermore, because higher levels of glycemia measures have also been associated with higher cardiovascular disease (CVD) incidence,^3,4 it has been proposed that including information on glycemia measures in algorithms used to predict the risk of CVD might be associated with improvements in the ability to predict CVD.^5-7